An Official Website of the United States Government
Company Information:
Name:
ARIETIS
Address:
650 Albany St
BOSTON, MA 02118-
BOSTON, MA 02118-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
THERAPY AGAINST RECALCITRANT C. albicans INFECTION
Award Year / Program / Phase:
2008 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Award Amount:
$599,243.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop an effective therapy against relapsing vaginosis caused by Candida albicans. The disease occurs in 8-9% of all women, and is recalcitrant to currently available therapies
. Upon adherence to a surface, C. albicans… More
2-adamantanamine Based Therapeutic for Recurrent Oropharyngeal Candidiasis
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Thomas A. Dahl
Award Amount:
$598,147.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase I project is to evaluate 2-adamantanamine compounds as a potential therapeutic to treat recurrent oropharyngeal candidiasis (OPC) in HIV patients. 2-adamantanamine is a close structural analog of
the antivirals amantadine and rimantadine,… More
Therapy Against Recalcitrant C. albicans Infection
Award Year / Program / Phase:
2010 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Thomas A. Dahl
Award Amount:
$2,984,771.00
Abstract:
DESCRIPTION (provided by applicant): One of the important unresolved problems in fungal antimicrobial chemotherapy is the ineffectiveness of existing therapeutics against cells that do no exist in a rapidly-growing, planktonic population. Upon attachment t
o abiotic surface or tissue, C. albicans… More
Compounds to treat Helicobacter pylori infection
Award Year / Program / Phase:
2012 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Kenneth Coleman – 978-729-0580
Award Amount:
$585,967.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to discover lead compounds acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Roughly every other person carries the pathogen, and there are an estimated 1.5 million cases… More
Narrow-spectrum Agents Acting against Helicobacter pylori
Award Year / Program / Phase:
2012 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Kenneth Coleman – 978-729-0580
Award Amount:
$297,456.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Roughly every other person carries the pathogen, and thereare an estimated 500,000 cases annually of… More